Literature DB >> 28918203

Short-term effects of preoperative beta-blocker use for isolated coronary artery bypass grafting: A systematic review and meta-analysis.

Liangshan Wang1, Hong Wang1, Xiaotong Hou2.   

Abstract

OBJECTIVE: The use of preoperative beta-blockers has been used as a quality standard for patients undergoing coronary artery bypass grafting (CABG). However, the benefits of beta-blockers use before CABG remain controversial. We performed a systematic review and meta-analysis to investigate the short-term effects of preoperative beta-blocker use for patients undergoing isolated CABG.
METHODS: We searched PubMed, Embase, and the Cochrane Library for English articles published from inception to August 16, 2016. Observational studies comparing preoperative beta-blockers therapy or non-beta-blockers therapy were considered eligible for the current study.
RESULTS: Six observational studies with 1,231,850 patients were included. The pooled analyses of unadjusted outcome (odds ratio [OR], 0.82; 95% confidence interval [CI], 0.71-0.95; P = .007) or risk-adjusted outcome (OR, 0.95; 95% CI, 0.92-0.97; P = .000) showed slight reduction in operative mortality, whereas an insignificant difference in mortality rate was observed in pooling postoperative data from propensity score analysis (OR, 0.97; 95% CI, 0.94-1.00; P = .088). Removing one study that used propensity-score covariate adjustment, subgroup analysis of propensity-matched patients (313,417 in each group) still generated a statistically nonsignificant benefit for preoperative beta-blocker use (OR, 0.97; 95% CI, 0.94-1.00; P = .093). Furthermore, the preoperative use of beta-blockers did not reduce the incidence of major postoperative complications, such as postoperative myocardial infarction, stroke, atrial fibrillation, reoperation, renal failure, prolonged ventilation, and sternal wound infection.
CONCLUSIONS: Our study suggests that the use of preoperative beta-blockers did not reduce either operative mortality or the incidence of postoperative complications in patients undergoing CABG.
Copyright © 2017 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary artery bypass grafting; operative mortality; perioperative beta-blocker use

Mesh:

Substances:

Year:  2017        PMID: 28918203     DOI: 10.1016/j.jtcvs.2017.08.025

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

Review 1.  Contemporary personalized β-blocker management in the perioperative setting.

Authors:  Adriana D Oprea; Xiaoxiao Wang; Robert Sickeler; Miklos D Kertai
Journal:  J Anesth       Date:  2019-10-21       Impact factor: 2.078

Review 2.  Preoperative, Multidisciplinary Clinical Optimization of Patients with Severely Depressed Left Ventricular Ejection Fraction Who Are Undergoing Coronary Artery Bypass Grafting.

Authors:  Islam Mohammad Shehata; Tiffany D Odell; Amir Elhassan; Maxim Spektor; Ivan Urits; Omar Viswanath; George M Jeha; Elyse M Cornett; Alan D Kaye
Journal:  Cardiol Ther       Date:  2020-12-23

3.  Preoperative beta-blocker in ventricular dysfunction patients: need a more granular quality metric.

Authors:  Hanwei Tang; Kai Chen; Jianfeng Hou; Xiaohong Huang; Sheng Liu; Shengshou Hu
Journal:  BMC Cardiovasc Disord       Date:  2021-11-19       Impact factor: 2.298

4.  Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery.

Authors:  Hermann Blessberger; Sharon R Lewis; Michael W Pritchard; Lizzy J Fawcett; Hans Domanovits; Oliver Schlager; Brigitte Wildner; Juergen Kammler; Clemens Steinwender
Journal:  Cochrane Database Syst Rev       Date:  2019-09-23

5.  Beta blockers and long-term outcome after coronary artery bypass grafting: a nationwide observational study.

Authors:  Martin Lindgren; Susanne J Nielsen; Erik Björklund; Aldina Pivodic; Sossio Perrotta; Emma C Hansson; Anders Jeppsson; Andreas Martinsson
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2022-08-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.